Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.

Summary

The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs. This study is intended for participants who are currently receiving alpelisib in a Novartis-sponsored clinical trial (parent study) and, in the Investigator's judgment, would benefit from continued treatment with alpelisib.

Timeline

Start

2026-12-15

Primary completion

2032-03-23

Completion

2032-04-20

Drugs

Indications